A prominent U.S. lawmaker may be upset that AbbVie (ABBV) ties the bonus given chief executive Richard Gonzalez to sales of the Humira rheumatoid arthritis treatment, but most shareholders seem unconcerned.

At the drug maker’s annual meeting on Friday, an overwhelming majority of stockholders rejected a proposal that would have required AbbVie to compile an annual report on how pricing is used to set executive compensation, according to a coalition of faith-based investor groups that submitted the proposal. On a preliminary basis, 69% of shareholders voted down the proposal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I obesrve that the erstwhile Mr Rea makes a sloppy comparison? “The dollar you need today to buy Humira is not as powerful as it was in 2007.” True but that means the price in 2007 of $17,160 would be worth $21,038 USD today. The delta between that number and the current price of $67,253 USD is still quite an increase but closer to 225% than the 300% he posits.
    [Inflation calculation courtesy of https://www.usinflationcalculator.com/ ]

    • Ah, I fogot to add the beloved caveat about the price difference ‘before applicable discounts and rebates’ ….. whatever they really are in this case.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy